From the secondary analysis, the significantly less conservative but clinically meaningful criterion of steady response (described to be a 50% or more reduction in MADRS from baseline for 2 weeks) was used. In the patients who accomplished secure response, twenty five.eight% during the esketamine group and fifty seven.6% from the placebo group rela